Showing 1811-1820 of 3366 results for "".
On the Leading Edge, Not the Bleeding Edge: Joe Niamtu, DMD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/on-the-leading-edge-not-the-bleeding-edge-joe-niamtu-dmd/18606/Innovator, influencer, and podium perennial Joe Niatmu, III, DMD has built a successful surgical aesthetic practice by focusing on the basics, concentrating on his strengths, and avoiding passing fads. How does he stay passionate, spot the best new developments, and build a fulfilling practice? In tDr. Ross Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-ross-discusses-experience-with-gemini-laser/19470/“There are a lot of new technologies out there, but one of the tried-and-true technologies is KTP laser and the long-pulse YAG laser. And the Gemini fits the bill for both of those wavelengths. So in a sense the Gemini is a time-tested product. It has served us well at our clinic, both at the NavyImproving Dermatologic Care and Access for Gender and Sexual Minority Patients
https://practicaldermatology.com/conferences/aad-2021/improving-dermatologic-care-and-access-for-gender-and-sexual-minority-patients/19919/Dermatologists need increased knowledge of health disparities and tools to best meet the needs of sexual and gender minority patients. From increased risk of skin cancer in sexual minority individuals to acne in the transgender population, there are many dermatologic concerns arising for patients, sAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and2022 in Review
https://practicaldermatology.com/topics/other-dermatology/2022-in-review/23833/The past year brought many new approvals and advances to dermatology for improved patient care.Topical Tretinoin: A Versatile Option for Adult Female Acne
https://practicaldermatology.com/issues/supplements/topical-tretinoin-a-versatileoption-for-adult-female-acne/23042/Findings of a roundtable discussion with leading acne experts on the benefits of retinoids for acne patients.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/Approvals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Updates on Nitric Oxide As a Topical Anti-infective
https://practicaldermatology.com/topics/practice-management/updates-on-nitric-oxide-as-a-topical-anti-infective/21071/NO continues to show promise as a safe and effective topical treatment candidate for acne and other infectious dermatoses.